Lowering LDL-C to <55 mg/dL in patients with atherosclerotic cardiovascular disease (ASCVD) reduced the rate of major cardiovascular events by one-third, according to the Ez-PAVE trial presented ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > Guidelines Search ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

The U.S. Food and Drug Administration (FDA) announced on May 1 that the Apple Atrial Fibrillation (AFib) History Feature now qualifies as a Medical Device Development Tool (MDDT) to assess AFib burden ...

The U.S. Food and Drug Administration (FDA) has approved Cardamyst™ (etripamil) nasal spray to treat adults with paroxysmal supraventricular tachycardia (PSVT). This rapid-acting, self-administered ...

The Diabetes and Cardiometabolic Disease Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical ...

A structured grocery home-delivery program aligned with the DASH (Dietary Approaches to Stop Hypertension) diet along with dietitian counseling significantly reduced systolic blood pressure (SBP) and ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, ...